Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial
Tango Therapeutics reported an 82% response rate and 88% nine-month progression-free survival in a pancreatic cancer trial. The company plans a global trial in 2027 and will focus on PRMT5 programs, reducing its workforce by 14%. Data from other trials is expected in January 2027, according to the company.
How this was made
The 30-second read
Why it matters
The disclosed response rates are unusually high for previously treated pancreatic cancer, potentially accelerating the company's path to a registrational trial.
Market read
Positive data could trigger a short‑term rally in TNGX and influence peer biotech valuations.
What to watch
Small patient cohort (22 evaluable) and upcoming larger registrational trial could alter expectations.
Background
Tango Therapeutics (TNGX) is a clinical‑stage biotech focused on PRMT5 inhibition.
Ticker impact
Tango Therapeutics disclosed an 82% objective response rate and 88% nine‑month PFS in a pancreatic cancer trial, a first‑report of pivotal data.
likely upward pressure as investors price in the high response rate
First disclosure of strong efficacy data for a late‑stage oncology asset typically drives share price gains.
Market effects
May boost sentiment for biotech firms developing PRMT5 inhibitors.
Limited to US biotech sector.
Highlights progress in pancreatic cancer therapeutics worldwide.
Counterpoint
Skeptics may question durability of response and upcoming trial design risks.
Key entities
- CompanyTango Therapeutics
Biotech developing vopimetostat and related compounds.